Good morning, everyone, and how are you today? 'Tis the middle of the week which, no doubt, means that this will be a challenging day. Those of you in need of a change of pace may want to tune in to our webinar today at 1 pm ET on the Sunshine Act (please see this). Meanwhile, we must now brew a needed cup of stimulation and busy ourselves with assorted documents. Have a great one...
FDA To Hold Meeting On Technology And Rx-To-OTC Switch (Drug Store News)
Concert Gets $200M From Avanir To Make Psych Drugs (Xconomy)
Abbott To Pay Galapagos Up To $1.35B For Arthritis Drug (Bloomberg News)
More Drugs Are Being Approved For Kids With Rare Disorders (Reuters)
Obesity, Vivus And Takeover Talk (Bloomberg News)
PhRMA Slams South Korea As Free Trade Pact Nears (Pharma Times)
Pills Are As Good As Stents For Some Patients: Study (Reuters)
German Public Health Funds Save 25 Percent Due To Generics (Pharma Times)
Pfizer Endorses Cynamid Remediation Plan (The Star-Ledger of NJ)
Biogen Seeks FDA OK For Needleless MS Treatment (Boston Globe)
Pfizer Recalls Lot Of Expired Prevnar Vaccine (Associated Press)
EDITOR'S NOTE: Please check this post for updates throughout the morning